Nephroprotection by SGLT2 Inhibition: Back to the Future?

Area of Science:

• Nephrology
• Endocrinology
• Pharmacology

Background:

• Sodium/glucose cotransporter 2 inhibitors (SGLT2i) offer new therapeutic avenues for chronic kidney disease (CKD) management in diabetic patients.
• Real-world evidence confirms the nephroprotective effectiveness of SGLT2i, extending potential benefits to non-diabetic populations.
• Despite proven organ protection, clinical utilization of SGLT2i remains limited.

Purpose of the Study:

• To explore the reasons behind the underutilization of SGLT2i in clinical practice.
• To re-evaluate the significance of the acute glomerular filtration rate (GFR) decline observed early in SGLT2i therapy.
• To connect the GFR "check-mark" sign with fundamental CKD treatment goals.

Main Methods:

• Review of recent large-scale real-world studies on SGLT2i efficacy.
• Analysis of randomized trial data on SGLT2i nephroprotective effects.
• Comparison of early GFR changes with traditional nephroprotective interventions.

Main Results:

• SGLT2i demonstrate confirmed nephroprotective efficacy in real-world settings.
• Positive results suggest benefits for both diabetic and non-diabetic individuals.
• An initial acute decline in GFR is a common, albeit concerning, early treatment response.

Conclusions:

• The early GFR decline with SGLT2i mirrors responses to established nephroprotective strategies.
• This phenomenon should prompt a renewed focus on alleviating hyperfiltration to preserve nephron function in CKD.
• Understanding and contextualizing the GFR "check-mark" sign is crucial for optimizing SGLT2i therapy and improving CKD outcomes.